Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer
Phase 2
Completed
NCT02876302
| Condition | Inflammatory Breast Cancer |
|---|
| Phase | Phase 2 |
|---|
| Sponsor | Dana-Farber Cancer Institute |
|---|
| Status | Completed |
|---|
| Enrollment | 23 participants |
|---|
| Interventions | Ruxolitinib, Paclitaxel, Doxorubicin, Cyclophosphamide |
|---|
| Start date | Jan 24, 2018 |
|---|
| Completion date | Dec 31, 2022 |
|---|
| Results posted | Apr 18, 2024 |
|---|
Summary
This research study is studying Ruxolitinib as possible treatment for Inflammatory Breast Cancer (IBC). The Following drugs will be use in combination with Ruxolinitinib. * Paclitaxel (also called Taxol) * Doxorubicin also called Adriamycin * Cyclophosphamide, also called Cytoxan
Biologic Response To 7-Day Run-In Window Phase Treatment of Ruxolitinib Alone or Ruxolitinib Plus Paclitaxel
7 days · Participants
| Ruxolitinib Alone First | 2 Participants |
|---|
| Ruxolitinib Plus Paclitaxel First | 3 Participants |
|---|
| Ruxolitinib Alone First | 9 Participants |
|---|
| Ruxolitinib Plus Paclitaxel First | 6 Participants |
|---|
| Ruxolitinib Alone First | 0 Participants |
|---|
| Ruxolitinib Plus Paclitaxel First | 3 Participants |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.